Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE

Jupiter Topco LLC purchased a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,072,494 shares of the company’s stock, valued at approximately $25,965,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP purchased a new stake in Monte Rosa Therapeutics during the 2nd quarter valued at about $30,000. Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics in the 3rd quarter worth approximately $32,000. Lazard Asset Management LLC increased its stake in Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the period. Prudential Financial Inc. bought a new stake in Monte Rosa Therapeutics in the second quarter valued at approximately $54,000. Finally, Seven Fleet Capital Management LP bought a new stake in Monte Rosa Therapeutics in the fourth quarter valued at approximately $63,000. 79.96% of the stock is owned by institutional investors.

Insider Activity at Monte Rosa Therapeutics

In related news, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares in the company, valued at $231,100. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the transaction, the insider directly owned 67,845 shares in the company, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 79,603 shares of company stock worth $1,725,081. 6.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GLUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Wedbush lowered their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, August 3rd. TD Cowen raised shares of Monte Rosa Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Monte Rosa Therapeutics in a report on Tuesday. Finally, Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.50.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $13.38 on Friday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.60 and a fifty-two week high of $25.77. The stock has a 50 day simple moving average of $19.72 and a two-hundred day simple moving average of $18.63. The stock has a market cap of $1.14 billion, a P/E ratio of -7.60 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $8.97 million for the quarter, compared to analysts’ expectations of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. Sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.32 earnings per share for the current year.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.